X
<

Who's Watching TEVA Now?

PART:
1 2 3 4 5 6 7 8 9
Part 3
Who's Watching TEVA Now? PART 3 OF 9

How TEVA’s Generic Medicines Franchise Is Positioned after 1H17

TEVA’s generic medicines revenue trends

In 1H17, Teva Pharmaceutical Industries’ (TEVA) generic medicines business generated revenues of ~$6.1 billion, or ~22% higher YoY (year-over-year). In 2Q17, this business generated revenues of ~$3.1 billion, or ~20% higher YoY and 1% higher QoQ (quarter-over-quarter).

In 1H17, TEVA’s OTC (over-the-counter) products generated revenues of $547 million, or ~2% lower YoY. In 2Q17, OTC products reported revenues of ~$283 million, or ~6% higher YoY and 7% higher QoQ.

How TEVA&#8217;s Generic Medicines Franchise Is Positioned after 1H17

Interested in TEVA? Don't miss the next report.

Receive e-mail alerts for new research on TEVA

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In 1H17, TEVA’s API (active pharmaceutical ingredients) products reported revenues of ~$401 million, or ~1% lower YoY. In 2Q17, API products generated revenues of ~$204 million, or ~1% lower YoY but ~4% higher QoQ.

Geographical revenues

In 2Q17, in the US, TEVA’s generic medicines business generated revenues of ~$1.3 billion, compared with ~$892 million in 2Q16. In US and European markets, generic medicines generated revenues of ~$957 million and $831 million, respectively, compared with $771 million and $897 million in 2Q16.

In 1H17, in the US, generic medicines generated revenues of ~$2.7 billion, compared with ~$1.9 billion in 1H16. In US and European markets, generic medicines generated revenues of ~$1.9 billion and $1.5 billion, respectively, compared with $1.56 billion and $1.59 billion in 2Q16.

TEVA’s peers include Novartis (NVS) (through Sandoz), Pfizer (PFE) (through Hospira), Sun Pharmaceuticals, GlaxoSmithKline, and Mylan (MYL). Notably, the PowerShares International Dividend Achievers Portfolio (PID) has ~0.87% of its total portfolio holdings in TEVA.

X

Please select a profession that best describes you: